2-Fluoromethamphetamine (2-FMA) is a stimulant drug of the amphetamine family which has been used as a designer drug . 2-FMA is commonly compared to lisdexamfetamine (Vyvanse), and dextroamphetamine due to its efficacy as a study or productivity aid. 2-FMA is purported to produce somewhat less euphoria than comparable amphetamines, likely due to its main mechanism of action consisting of norepinephrine reuptake inhibition.
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||167.227 g·mol−1|
|3D model (JSmol)|
|(what is this?) (verify)|
2-Fluoromethamphetamine is fluorinated analogue of methamphetamine, and is a regioisomer of 3-FMA and 4-FMA.
It does not activate the serotonin receptors, including 5-HT2A, unlike most stimulant drugs of the amphetamine family.
As of 1996, 2-FMA is a controlled substance in Canada, due to being an analog of methamphetamine.
As of October 2015, 2-FMA is a controlled substance in China.
As of 13 December 2014, 2-FMA is a controlled substance in Germany. It is controlled under Anlage I BtMG (Narcotics Act, Schedule I). Substances controlled under Anlage I BtMG are illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license. Violations of the law are punishable by a fine or imprisonment for up to five years.
As of July 2019, 2-FMA is a controlled substance in Ukraine (considered a narcotic).
As a close analog of scheduled controlled substance, sale or possession of 2-FMA could be potentially be prosecuted under the Federal Analogue Act.